Revision 1

#8767 Store at -20C

CCN3 Antibody

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355) orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source:	UniProt ID:	Entrez-Gene Id:
WB	H M R Mk	Endogenous	43	Rabbit	#P48745	4856

Product Usage Information

Application	Dilution
Western Blotting	1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

CCN3 Antibody recognizes endogenous levels of total CCN3 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg118 of human CCN3 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

CCN3, also named NOV (Nephroblastoma overexressed), belongs to the CCN (Cyr61, Ctgf, NOV) family of proteins. It is a cystine-rich secretory protein that associates with components of the extracellular matrix. Like other CCN family members, CCN3 is capable of mediating diverse biological functions through its four distinct domains, which enable binding to numerous protein partners (1-5).

CCN3 modulates bone turnover through various mechanisms and is implicated in the progression of primary bone cancers such as osteosarcoma and chondrosarcoma (6-8). Research has shown that CCN3 is also involved in the bone metastasis of melanoma, breast cancer, and prostate cancers (9-11). Recently, CCN3 was reported to play an important role in stem cell renewal (12). CCN3 is normally expressed in both embryonic and adult tissues (13,14). The activity of CCN3 is influenced by post translational modifications and proteolytic cleavage (15,16).

Background References

1. Perbal, B. (2001) *Mol Pathol* 54, 57-79.
2. Brigstock, D.R. et al. (2003) *Mol Pathol* 56, 127-8.
3. Leask, A. and Abraham, D.J. (2006) *J Cell Sci* 119, 4803-10.
4. Yeger, H. and Perbal, B. (2007) *J Cell Commun Signal* 1, 159-64.
5. McCallum, L. and Irvine, A.E. (2009) *Blood Rev* 23, 79-85.
6. Perbal, B. et al. (2008) *Clin Cancer Res* 14, 701-9.
7. Tzeng, H.E. et al. (2011) *J Cell Physiol* 226, 3181-9.
8. Yang, W. et al. (2011) *Hum Reprod* 26, 2850-60.
9. Vallacchi, V. et al. (2008) *Cancer Res* 68, 715-23.
10. Ouellet, V. et al. (2011) *Am J Pathol* 178, 2377-88.
11. Chen, P.C. et al. (2012) *Carcinogenesis* 33, 937-45.
12. Gupta, R. et al. (2007) *Science* 316, 590-3.
13. Burren, C.P. et al. (1999) *J Clin Endocrinol Metab* 84, 1096-103.
14. Kocialkowski, S. et al. (2001) *Anat Embryol (Berl)* 203, 417-27.
15. Perbal, B. et al. (1999) *Proc Natl Acad Sci U S A* 96, 869-74.
16. Su, B.Y. et al. (2001) *Mol Pathol* 54, 184-91.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

WB: Western Blotting

Cross-Reactivity Key

H: human **M:** mouse **R:** rat **Hm:** hamster **Mk:** monkey **Vir:** virus **Mi:** mink **C:** chicken **Dm:** D. melanogaster
X: Xenopus **Z:** zebrafish **B:** bovine **Dg:** dog **Pg:** pig **Sc:** S. cerevisiae **Ce:** C. elegans **Hr:** horse
GP: Guinea Pig **Rab:** rabbit **All:** all species expected

Trademarks and Patents

Limited Uses